Novo Nordisk A/S
Novo Nordisk A/S
11/08/2024 | Press release | Distributed by Public on 11/08/2024 15:55
Novo Nordisk A/S – Share repurchase programme Form 6 K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 8, 2024
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 8 November 2024 - The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 3,136,206,122.30 in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
The purpose of the programme is to reduce the company's share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 11 November 2024 and ending on 3 February 2025. A maximum of 400,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
|
Ambre James-Brown +45 3079 9289 |
Liz Skrbkova (US) +1 609 917 0632 |
| Investors: | |
|
Jacob Martin Wiborg Rode +45 3075 5956 |
David Heiberg Landsted +45 3077 6915 |
|
Sina Meyer +45 3079 6656 |
Ida Schaap Melvold +45 3077 5649 |
|
Frederik Taylor Pitter +1 609 613 0568 |
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 85 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 8, 2024 |
NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer |